Popular on EntSun
- Top Edu-Tainment IP, Badanamu, enters children's mental health space, launching Healthy Kids Music Network - 451
- Buildout Unveils Rethink+: Revolutionizing Commercial Real Estate Prospecting with Seamless CRM Integration - 436
- HollyShorts Film Festival Celebrates 21 Years and selects '12 HOURS' For 2025 line-up - 427
- Final Clearance to Close Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA); $750 Million Ketamine Therapy Market - 423
- Vitanergy Health US Inc. Launches Three New Dietary Supplements to Support Women's Daily Wellness - 411
- Phinge®, Home of Netverse® and Netaverse™ With Verified and Safer AI Announces "Test the Waters" Campaign for Potential Regulation A+ Offering - 367
- EMBER™, the Only Standardized System Linking Workforce Identity to Growth, Appoints Global Brand Visionary Bret Sanford-Chung to Board of Directors - 366
- $3 Billion Suicidal Depression Market Advancements on Multiple Fronts, Highlighted by FDA Fast Track Designation for Effective NRX 100 Drug Therapy - 360
- Ubleu Crypto Group Achieves FinCEN Registration and Colorado Incorporation, Accelerating U.S. Market Entry - 341
- The 2025 "Aizu Festival" in Aizu Wakamatsu City will be held September 19–21 - 288
Similar on EntSun
- BusinessRate Selects New Jersey Therapy & Life Coaching as Best Couselors
- Lineus Medical and Venture Medical Sign New Zealand Distribution Agreement
- PermianMuseum.com adds Interstellar Visitor Video Gallery
- Mrs. Field's Closet Expands to Minot North High School
- Lowcountry Male and AquaVitae Announce New Clinic Opening in Savannah, Georgia
- CCHR Warns Global Survey Confirms Electroshock Risks Hidden From Public
- Sober.Buzz Adds Second Podcast, "Spreading the Good BUZZ" Guest List Grows, Numbers Continue Growing Globally, All While Josh and Heidi Tied the Knot
- Dr. Friedberg & Associates Brings Life-Changing All-on-4 Dental Implants and Comprehensive Smile Solutions to Houston
- Dr. Sanju P. Jose Highlights Expertise in Periodontics and Implant Dentistry
- $3 Billion Suicidal Depression Market Advancements on Multiple Fronts, Highlighted by FDA Fast Track Designation for Effective NRX 100 Drug Therapy
IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
EntSun News/11038291
IGC Pharma, Inc. (NYSE American: IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database.
IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
POTOMAC, Md. - EntSun -- IGC Pharma, Inc. (NYSE American: IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database.
The PREPARE Challenge, is sponsored by the National Institute on Aging ("NIA"), an institute of the National Institute of Health ("NIH"). The competition aims to accelerate the development of more accurate, innovative, and representative tools for Alzheimer's and related dementias. The Disproportionate Impact prize recognizes the submission with the most potential to support algorithms that generalize to populations disproportionately impacted by AD/ADRD.
IGC's entry in Phase 1 of the PREPARE Challenge won 3rd prize overall and the Disproportionate Impact prize. "We are honored to win the two PREPARE prizes. These recognitions underscore IGC's leadership in artificial intelligence ("AI") and deep learning research aimed at improving Alzheimer's disease prediction," commented CEO Ram Mukunda.
There are approximately 400 million individuals in the preclinical stage of Alzheimer's exhibiting early brain changes, such as plaque buildup, that could lead to cognitive decline within 20 years. By harnessing deep learning models, IGC is developing scalable and cost-effective diagnostic predictors that bypass expensive imaging techniques and ultimately predict cognitive decline two decades before symptoms manifest.
More on EntSun News
Early prediction improves patient outcomes and can help significantly reduce caregiving and healthcare costs.
Ram Mukunda continued, "We believe our early prediction AI initiatives can offer significant hope to patients and caregivers, create long time value for shareholders, and alleviate the projected $1 trillion economic burden on the U.S. healthcare system from Alzheimer's disease."
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.
More on EntSun News
Forward-looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Q filed with the SEC on August 7, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contacts
IMS Investor Relations
Rosalyn Christian / Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
The PREPARE Challenge, is sponsored by the National Institute on Aging ("NIA"), an institute of the National Institute of Health ("NIH"). The competition aims to accelerate the development of more accurate, innovative, and representative tools for Alzheimer's and related dementias. The Disproportionate Impact prize recognizes the submission with the most potential to support algorithms that generalize to populations disproportionately impacted by AD/ADRD.
IGC's entry in Phase 1 of the PREPARE Challenge won 3rd prize overall and the Disproportionate Impact prize. "We are honored to win the two PREPARE prizes. These recognitions underscore IGC's leadership in artificial intelligence ("AI") and deep learning research aimed at improving Alzheimer's disease prediction," commented CEO Ram Mukunda.
There are approximately 400 million individuals in the preclinical stage of Alzheimer's exhibiting early brain changes, such as plaque buildup, that could lead to cognitive decline within 20 years. By harnessing deep learning models, IGC is developing scalable and cost-effective diagnostic predictors that bypass expensive imaging techniques and ultimately predict cognitive decline two decades before symptoms manifest.
More on EntSun News
- Where Are They Now Radio Show Celebrates 5-Year Anniversary on WCPT-820AM
- Brash Enterprises Launches Brash & Bold Future Speak YouTube Channel
- Integris Composites Joins Pacific Future Forum in Tokyo
- Brash Enterprises LLC Launches Brash & Bold Studios: A Minimalist Media Company for Unfiltered Storytelling
- Artest Management Group Celebrates Successful Launch at LA Creator Space
Early prediction improves patient outcomes and can help significantly reduce caregiving and healthcare costs.
Ram Mukunda continued, "We believe our early prediction AI initiatives can offer significant hope to patients and caregivers, create long time value for shareholders, and alleviate the projected $1 trillion economic burden on the U.S. healthcare system from Alzheimer's disease."
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.
More on EntSun News
- Doberman Pup Explores Off-Grid Island in New Outdoor Adventure Release
- Sandbox Studio South Proudly Presents Jackson County Line Live in Concert on Youtube: @SandboxStudioSouth
- BusinessRate Selects New Jersey Therapy & Life Coaching as Best Couselors
- IRL Investigations Combines Decades of Experience with Modern Digital Expertise
- New Leadership Model – Never Fire Anyone – Released Today
Forward-looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Q filed with the SEC on August 7, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contacts
IMS Investor Relations
Rosalyn Christian / Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
Contact
IMS Investor Relations
Rosalyn Christian / Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
IMS Investor Relations
Rosalyn Christian / Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
Source: IGC PHARMA
Filed Under: Health
0 Comments
Latest on EntSun News
- Phinge's® One-Of-A-Kind Modular Earbuds With Stylish Interchangeable Battery Modules & Dual Charging Case Available Soon for Pre-Sale
- Victoria Carson's Powerful Anthems of Justice!
- Growth Acceleration via Strategic Reverse Split After $10 Million Acquisition for Concerts.com and TicketStub.com; AI Powered Sports/Entertainment Co
- OddsTrader Projects Three Potential Elimination Games in Week 1 of College Football
- Century Fasteners Corp. Exhibiting at the 2025 International Fastener Expo
- 2 Funny Native Comedy Night Comes To Kwa Tuq Nuk Casino
- Canvas Cloud AI Launches to Transform Cloud Education From Memorization to Mastery
- The Squires Group Becomes a Workday Partner
- Voices for Humanity Stands Up for Human Rights with Isabelle Vladoiu
- Meet a Scientologist Reveals the Art of Leather Alchemy with Iccio and Michele Leonelli
- From Comedy To Culture: Ali Siddiq And Terri J. Vaughn Embrace Living Differently
- From Vernon Hills to Mensa Before Kindergarten
- Fine Arts Festival Downtown Downers Grove
- PermianMuseum.com adds Interstellar Visitor Video Gallery
- What if Cinderella Left the Ball Drunk, Heartbroken, and Tangled in a Love Triangle?
- SOBREO Elixirs Debut in New York City, Defining a New Era in Inclusive Hospitality
- Comedy Hypnotist comes to San Antonio's Deco Ballroom September 5 & 6 with his Mind Boggling Tour
- Allen Field to Showcase Sustainable Paper Handle Applicator at PACK EXPO Las Vegas 2025
- Riverdale receives grant to bring accessibility to Clark Park
- 9th Annual A Taste of the Deep South Festival Announces the Talent Line-up and Sponsors